AI assistant
BIOMARIN PHARMACEUTICAL INC — Director's Dealing 2014
Jan 6, 2014
30583_dirs_2014-01-06_3f58e10b-6d34-45b3-bc69-c367dd10c753.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK: 0001048477
Period of Report: 2014-01-02
Reporting Person: BIENAIME JEAN JACQUES (Director, Chief Executive Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2014-01-02 | Common Stock | M | 5000 | $12.99 | Acquired | 55740 | Indirect |
| 2014-01-02 | Common Stock | S | 5000 | $68.8965 | Disposed | 50740 | Indirect |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2014-01-02 | Stock Option (right to buy Common Stock) | $12.99 | M | 5000 | Disposed | 2016-05-10 | Common Stock (5000) | Indirect |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 10000 | Indirect |
| Common Stock | 10000 | Indirect |
| Common Stock | 10000 | Indirect |
| Common Stock | 10000 | Indirect |
| Common Stock | 20000 | Indirect |
Footnotes
F1: Transaction made pursuant to a Rule 10b5-1 trading plan executed on February 26, 2013.
F2: The reporting person and his spouse act as trustees for the Bienaime Family Trust.
F3: The price in column 4 is a weighted average price. The price actually received ranged from $68.58 to $69.95. The reporting person will provide to the issuer, any security holder of the issuer, ot th SEC staff, upon request, information regarding the number of shares sold at rach price within the range.
F4: The reporting person's spouse is trustee of each child's trust.
F5: Original option grant vests 6/48th on November 11, 2006, and 1/48th on the 11th day of every month thereafter
F6: Reflects the number of stock options outstanding after the transaction from this specific stock option grant.